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RetrotransposonThe antisense promoter of human LINE-1 (L1) retroelements can direct transcription of adjacent unique
genomic sequences generating chimeric RNAs, which can perturb transcription of neighbouring genes. As L1
elements constitute 17% of the human genome, chimeric transcription is potentially widespread, but the
extent to which this occurs is largely unknown. Using a genome-wide screen we have isolated novel
chimeric transcripts that are unique to breast cancer cell lines, primary tumours and colon cancer cells.
Expression of the cancer-speciﬁc chimeric transcripts can be induced in non-malignant breast epithelial cells
by the demethylating drug 5-azacytidine. These ﬁndings indicate that loss of L1 methylation in cancer cells is
linked to the expression of L1-chimeric transcripts which may therefore constitute a useful set of markers of
malignancy.
© 2009 Elsevier Inc. All rights reserved.Introduction
LINE-1 (L1) retrotransposons are the most common autonomous
elements in the human genome comprising 17% of the DNA [1]. Full-
length L1 elements consist of 5′ and 3′ untranslated regions (UTR) and
twoopen reading frames that encodegenes for retrotransposition (ORF-
1 andORF-2) (Fig. 1A). The 5′UTR contains a bidirectional promoter: the
sense promoter transcribes the two open reading frames and the
antisense promoter (ASP) can direct transcription of the adjacent
genomic DNA [2]. However, the majority of the estimated 500,000
copies of L1 elements present in the human genome are truncated,
rearranged, or mutated and only 177 of the about 7000 extant full-
length elements are potentially retrotransposition-competent [3].
L1 elements, even those lacking retrotransposition capacity, can
inﬂuence the transcription of the unique sequences within a cell,
contributing to the regulation and diversity of gene expression
patterns. For example, intronic L1 elements can provide alternative
splice and polyadenylation sites [4,5] and inﬂuence transcript levels of
the host gene [6,7]. Furthermore, the L1 antisense promoter can
transcribe regions of unique sequence leading to the production of
chimeric transcripts found in a variety of cell types [2,8]. The LINE-1
ASP (L1-ASP) can act as a tissue-speciﬁc promoter and, depending on
the relative orientations of the L1 and the cellular genes, L1-ASP can
drive sense or antisense transcription leading to alternative spliceC. Tufarelli).
ll rights reserved.variants of several cellular genes or antisense RNAs containing regions
of complementarity to exons of mRNAs [9]. Moreover, it has been
recently reported that the majority of natural antisense transcripts
initiate at L1 elements [10] and as antisense transcription can alter the
local chromatin structure and lead to gene activation [11–13], or
silencing [14–16], these transcripts have the potential to inﬂuence
gene expression patterns; however, few studies have looked at this in
detail.
Some reports implicate chimeric transcripts in cancer. For
example, a cancer-speciﬁc L1-ASP-driven transcript was identiﬁed
in oesophageal adenocarcinoma [17]. In addition, activation of an L1
in the ﬁrst intron of the MET proto-oncogene leads to L1-ASP-driven
transcription of a truncated isoform of this gene which is associated
with increased risk of progression to blast crisis in chronic myeloid
leukaemia patients and decreased levels of methylation at L1
elements [18].
Hypomethylation at repetitive DNA is a general feature of cancer
cells [19]. The molecular mechanisms underlying cancer-related loss
of methylation are largely unknown [20], but there is strong evidence
indicating that hypomethylation plays an active role in cancer
progression. In mouse models, loss of the maintenance DNA
methyltransferse, Dnmt1, leads to hypomethylation, activation of
retroelements, and susceptibility to tumours [21,22]; moreover, in
some human cancers, there is a direct correlation between the
severity of the disease and the decrease in methylation at the L1
promoter [23]. Indeed, loss of methylation and activation of
transposable elements have been proposed as factors promoting
malignancy progression [21,22,24]. One hypothesis suggests that L1
hypomethylation leads to an increase in retrotransposition and
Fig. 1. LINE-1 chimera display (LCD) Technique. (A) Schematic diagram of full-length LINE-1 element showing its sense (SP) and antisense promoters (ASP), ORFs required for
retrotransposition and the 5′ and 3′ UTRs. The scale is in base pairs. Below is an enlargement of the 5′UTR region, the HpaII restriction sites and the regulatory CpG rich region. (B)
Schematic representation of the LCD technique. Shown are the 4 main stages of the technique: conversion of total RNA to double-stranded cDNA (I). The cDNA is digested with a
restriction enzyme (in this case XbaI) that does not cut within L1-ASP, and complementary adapters are ligated onto the overhangs (II). These adapters have a high CG content and
form panhandle structures which only permit the ampliﬁcation of those containing a binding site for the L1-speciﬁc primer RB5PA2 with the adapter-speciﬁc primer 42c (III). Nested
PCR is carried out using primers 20a (L1-speciﬁc, panel A) and 42d (IV), PCR products can be cloned into a library or visualised by electrophoresis. (C) Visualisation of LCD products
from normal breast and the MCF-7 cancer cell line. Gel electrophoresis shows many LINE-1 chimeric transcripts in the cancer cell line than in normal breast.
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methylation of retroelements is an important mechanism to prevent
retrotransposition in somatic cells [28,29]. Despite this, evidence of
augmented transposition in tumours is scant [20] and the effects that
hypomethylation has on the transcriptional activation of L1 promo-
ters leading to the genome-wide production of chimeric transcripts
are not understood.
Here, we have developed a genome-wide RT–PCR based technique,
L1 chimera display, to isolate novel L1-chimeric transcripts and
compare the levels of expression of these in normal and cancer cell
lines. Furthermore, we have used a tissue culture system to
investigate the role of global hypomethylation in their regulation in
cancer cells.
Results
Isolation of L1-chimeric transcripts (L1 chimera display)
L1 chimera display (LCD) was developed to amplify and display
RNAs containing L1-ASP and unique sequences, hereafter referred to
as L1-chimeric transcripts (LCT). This method is a modiﬁcation of a
technique used to amplify transcripts containing HERV K LTRs [30]and is schematically represented in Fig. 1B (see Materials and
methods for details). Double-stranded cDNA is synthesised from
total RNA (I). The cDNA is digested with a restriction enzyme which
does not cut within the L1-ASP sequence and adapter linkers are
ligated into the overhangs created (II). Nested PCR is performed using
a primer within the L1-ASP (RB5PA2 or 20a) and a primer speciﬁc to
the adapter region. The adapters are designed to allow suppression
PCR and prevent the ampliﬁcation of fragments that do not contain
the L1-ASP sequence [31]. The PCR products can then be displayed by
agarose gel electrophoresis or cloned into libraries.
A representative result of the LCD technique performed on total
RNA from normal and breast cancer cells is shown in Fig. 1C,
demonstrating an increase in the number of L1-chimeric transcripts in
MCF-7 breast cancer cells compared to normal breast. Using this
method, libraries of LCTs were generated from breast cancer cell lines
MCF-7, HCC-1954, and normal breast RNA. Table 1 lists the details of
eighteen LCTs cloned and sequenced by initial sampling of the
libraries. Eight of the sequenced LCTs contain entirely repetitive
sequences such as other LINE and LTR transposable elements.
Furthermore, ten of the transcripts sequenced were novel, contained
unique sequences, and could be mapped to speciﬁc genomic loci near
or within coding genes (Table 1).
Table 1
Identiﬁcation of LCTs isolated by LCD analysis from breast cancer cell lines and normal controls.
Name LINE-1 subfamily Chromosome LINE-1 annotationa
Contig : region
Adjacent genes Localisation with
respect to gene
Transcript orientation
with respect to gene
LCT1 L1MEg
LCT2 L1PA2 6q21 NT_025741 :29151280-29157305 TCBA1 (T-cell lymphoma breakpoint associated) Intronic, between
exons 4 and 5
Antisense
LCT3 L1PA6
LCT4 Repetitive
LCT5 L1PA10
LCT6 L1PA2 4q13 NT_022778 :C 7062289-7068291 LOC728048 (interferon induced
transmembrane protein psuedogene) and CENPC1
(centromere protein C1)
Intergenic
LCT7 L1HS 14q12 NT_026437 :C12153769-12159796 G2E3 (G2/M-phase speciﬁc E3 ubiquitin ligase) Intronic, between
exons 14 and 15
Sense
LCT8 L1HS 7q31 NT_007933 :C 36067159-36073180 IMMP2L – inner mitochondrial membrane
peptidase 2-like
Intronic, between
exons 2 and 3
Antisense
LCT9 L1PA2 7p15 NT_007819 :C 30165385-30171406 GARS (glycyl tRNA synthetase) and CRHR2
(corticotrophin-releasing hormone receptor-2)
Intergenic
LCT10 Repetitive
LCT11 L1PA16
LCT12 L1PA16
LCT13 L1HS 7q21 NT_007933 :18448133-18455357 CALCR (calcitonin receptor) and RPS27P17
(ribosomal protein S27 pseudogene 17)
Intergenic
LCT14 L1PA2 5p14 NT_006576 :C 25351398-25357424 LOC729826 and MSNL1 (moesin-like 1) Intergenic
LCT15 L1HS 5q21 NT_034772 :6269303-6275314 NUDT12 (nucleoside diphosphate linked
moiety X-type motif 12) and RAB9P1 (RAB9,
member RAS oncogene family, pseudogene 1)
Intergenic
LCT16 MLT1C (LTR)
LCT17 L1PA2 Xp22 NT_011757 :3280262-3286271 LOC347381 (hydroxyacyl-coenzyme A
dehydrogenase psuedogene) and NLGN4X
(neuroligin 4)
Intergenic
LCT18 L1PA4 8q11 NT_008183 :C 266788-271658 KIAA0146 (hypothetical protein) Intronic, between
exons 8 and 9
Sense
a Annotations are based on Built 35.1 of the human genome sequence. C preceding the region co-ordinates indicates that the LINE-1 is complementary to the contig sequence.
399H.A. Cruickshanks, C. Tufarelli / Genomics 94 (2009) 397–406A subset of L1-chimeric transcripts is breast cancer-speciﬁc
Seven of the new L1-chimeric transcripts identiﬁed by LCD were
validated by strand-speciﬁc RT–PCR in DNaseI-treated total RNA fromFig. 2. Validation of LINE-1 chimeric transcripts in breast cancer. (A) Strand-speciﬁc RT–PC
normal and breast cancer cell lines. Two normal breast tissue samples were analysed with ide
to exclude the possibility of contamination from genomic DNA and APRT acts as a positive c
breast tissue and from the cancer cell lines reveals that the L1 insertions under study are p
which is absent in HCT-1954 cells. (C) Strand-speciﬁc RT–PCR analysis of LCTs in total RN
individuals, suggesting an increase in LCTs expression in tumour tissues.two breast cancer cell lines and from two primary samples of normal
breast tissue from a commercial source (one representative normal
sample is shown in Fig. 2A). LCT8 and 9 are present in normal breast
and in cancer cell lines, LCT14, 15, and 17 are unique to MCF-7 cellsR analysis of 7 of the LCTs identiﬁed in the LCD screening procedure in total RNA from
ntical results, a single representative sample is shown. A negative RT control is included
ontrol for RNA quality and quantity. (B) PCR genotyping of genomic DNA from normal
resent in the cell types analysed with the exception of the L1HS associated with LCT15
A from primary breast tumours and matched adjacent normal tissue sourced from 5
Fig. 3. Identiﬁcation of LCTs initiating at L1-ASP. (A) Schematic diagram of a fragment of genomic DNA including non-L1 sequences (black line) and a L1 5′UTR, ORF-1, and part of
ORF-2. The L1 sense (SP) and antisense (ASP) promoters are indicated. Also shown are the primers used to investigate the potential of read-through transcription in the LCTs
analysed in this study: LCT refer to primers speciﬁc to the unique sequence of each of the seven LCTs analysed; 18e and 18f are primers within ORF-1. (B) RT–PCR analysis of seven
LCTs using the LCT-speciﬁc primers in combination with a primer within L1 ORF-1 (18f). Note that LCT8, LCT9, and LCT15 have read-through transcription, whereas LCT13, LCT14,
LCT17, and LCT18 are likely to originate at the L1 ASP. (C) Mapping to the L1 5′UTR of the sequences of the clones obtained by 5′RACE on LCT13 (LCT13_a and LCT13_b) and LCT14
(LCT14_a and LCT14_b) conﬁrms that these LCTs initiate at L1-ASP.
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These results are consistent with the display in Fig. 1C indicating that
more L1-containing transcripts are present in cancer cell lines than
normal controls.
As L1 insertions can be polymorphic among human populations,
the corresponding genomic DNA was analysed by PCR to determine if
the lack of expression of individual LCTs was due to absence of the L1
element. Only the L1 element associated with LCT15 is polymorphic
among the cell lines studied and not present in HCC-1954 (Fig. 2B).
Therefore, absence of LCT expression is more likely due to repression
of transcription rather than to polymorphic L1 insertions.
Expression of the LCTs was analysed in total RNA isolated from
primary tumours and matched adjacent normal breast tissue of ﬁve
independent breast cancer patients (Fig. 2C). Consistentwith the results
in Fig. 2A, LCT8 and 9 were found in both normal and tumour samples,
whilst all of the cancer-speciﬁc LCTs (LCT13–18), with the exception of
LCT14, are present or enhanced in one or more of the tumour samples
(Fig. 2C). It seems, therefore, that the differences observed between the
cell lines andnormal controls candistinguish a tumour from itsmatched
control, strengthening the correlation between expression of the
cancer-speciﬁc LCTs and a malignant phenotype.
L1-chimeric transcripts initiate at L1-ASP
The LCD technique isolates L1-ASP containing transcripts but is
unable to distinguish between LCTs that originate at L1-ASP and those
that are part of larger read-through transcripts. Using a retro-
transposition-competent transgenic construct L1-ASP initiation siteshave been mapped in the regions of +378 to +431 and +480 to
+497 [32]. Therefore, LCTs driven by L1-ASP should not contain L1-
ORF-1 sequences and no ampliﬁcation should be observed by RT–PCR
using a primer speciﬁc to the unique region and primers comple-
mentary to L1-ORF-1 (Fig. 3A). Strand-speciﬁc RT–PCR reveals that
LCT8, 9, and 15may be part of read-through transcripts initiating from
upstream promoters (Fig. 3B). In contrast, no product was obtained by
ampliﬁcation with ORF-1 primers 18e and 18f and the unique primer
in LCT13, 14, 17, and 18 (Fig. 3B and data not shown), suggesting that
they may originate from L1-ASP. To conﬁrm this, 5′RACE was
performed on LCT13 and LCT14 and two products were obtained for
each LCT which were cloned, sequenced, andmapped to the L1-ASP at
the respective genomic locations. This analysis revealed that LCT13
and LCT14 indeed initiate at L1-ASP, with transcription start sites for
LCT13_a and _b found at+160 and+197, respectively, for LCT14_a at
+495 and for LCT14_b at +180 (Fig. 3C). These ﬁndings suggest that
initiation of transcription at endogenous L1-ASP sequences is more
variable than what observed in the transgenic construct [32],
accounting for the initiation site mapping further downstream than
those observed in the retrotransposition-competent transgene, and
demonstrate that some of the cancer-speciﬁc LCTs that become active
during tumourigenesis are derived from L1-ASP.
L1-chimeric transcripts are also present in colon cancer
To assess whether LCT expression is a more general trait of cancer,
strand-speciﬁc RT–PCR analysis and genotyping was extended to total
RNA from normal colon and three colon cancer cell lines: HCT-116
Fig. 4. LINE-1-driven chimeric transcripts are expressed in colon cancer cell lines. (A) PCR genotyping of genomic DNA from normal colon and from the colon cancer cell lines
identiﬁes the L1HS associated with LCT15 as polymorphic and absent in HCT-116 and in SW480 and SW620. The SW480 and SW620 lines are isogenic and only the genotyping
results for SW480 are shown. (B) Strand-speciﬁc RT–PCR analysis of LCTs in total RNA isolated from colon cancer cell lines (HCT-116, SW480, and SW620) and commercially
available primary normal colon. A negative RT control is included to exclude the possibility of contamination from genomic DNA and APRT is used as a positive control. Note that
LCT13, LCT14, and LCT17 are expressed in the metastatic line SW620 but not in the isogenic adenocarcinoma line SW480.
401H.A. Cruickshanks, C. Tufarelli / Genomics 94 (2009) 397–406isolated froman invasive colorectal carcinoma, and a pair of isogenic cell
lines established from the same individual at two different stages of
malignancy; SW480 derived from colorectal adenocarcinoma and
SW620derived froma lymphnodemetastasis. PCRgenotyping conﬁrms
the presence of the seven L1 elements in the three cell lines, except for
the L1HS associatedwith LCT15which is absent in HCT-116 and SW480
and SW620, but present in the normal colon samples tested (Fig. 4A).
Strand-speciﬁc RT–PCR analysis of total RNA from the colon cancer
cell lines reveals that LCT18 is expressed in normal colon, suggesting a
different pattern of expression to normal breast, whilst expression of
the other LCTs is restricted to the cancer cell lines. Hence, similar to
observations in breast cancer cells, the presence of the L1 insertion is
not sufﬁcient for LCT expression and there is cancer-speciﬁc LCT
expression. It is noteworthy that the L1-driven transcripts LCT13, 14,
and 17 are found in the invasive SW620 and not in SW480 (Fig. 4B),
suggesting that their expression is associated with progression to an
invasive phenotype.
Increased expression of L1-ASP containing transcripts correlates with
DNA hypomethylation
Having showncancer-speciﬁc expression of LCTs in both breast and
colon cancer cells, and that their absence in normal cells is not merely
due to polymorphic L1 insertions, wewished to address themolecular
mechanism responsible for this activation. As L1 hypomethylation has
been observed in a wide range of cancers [33,34], and has been
proposed to activate an LCT at the MET gene [18], we examined the
correlation between global hypomethylation and expression of the
L1-ASP-driven LCTs identiﬁed in this study (LCT13, 14, 17, and 18).
Levels of DNAmethylation at L1 elements in breast cancer cell lines
were compared to those of normal breast samples by methylation-sensitive Southern blotting using the enzymes MspI, which is
insensitive to CpG methylation (Fig. 5A, odd numbered lanes), and
its methylation-sensitive isoschizomer HpaII (Fig. 5A, even numbered
lanes). A DNA probe spanning the L1 5′UTR (Fig. 1A) reveals that DNA
from the breast cancer cell lines is more readily cleaved by the
methylation-sensitive HpaII enzyme than a normal breast DNA
control, indicating that in these cell lines the L1 promoter is
hypomethylated (Fig. 5A). Complete digestion was conﬁrmed by
hybridisation with a mitochondrial DNA probe [35] (data not shown).
These data indicate that activation of L1-driven transcripts in breast
cancer cells correlates to loss of methylation at the L1 promoter.
To determine if hypomethylation is sufﬁcient to activate the cancer
cell-speciﬁc LCTs, we treated the MCF-10A cell line, a spontaneously
immortalized non-neoplastic human breast epithelial cell line with
characteristic of normal breast [36], with 5-azacytidine, an inhibitor of
DNA methylation, to induce global loss of DNA methylation, thus
mimicking cancer-related hypomethylation. Treated and untreated
cells were analysed by Southern blotting as described above, showing
that untreated MCF-10A cells have some degree of hypomethylation
compared to normal breast tissue, but 5-azacytidine treatment leads
to a further decrease (Fig. 5B). The decreases in L1-ASPmethylation in
MCF-7 compared to normal breast (Fig. 5A) and in 5-azacytidine-
treated MCF-10A cells relative to untreated cells (Fig. 5B) are
associated with an increase in transcripts containing the L1-ASP
promoter, including read-through transcripts, as shown by semi-
quantitative RT–PCR (Fig. 5C). Two-dimensional densitometry analy-
sis was performed to determine the levels of L1-ASP containing
transcripts relatively to two internal controls, the single-copy gene
APRT and the multi-copy gene for the 18S ribosomal subunit (Figs.
5D and E). When comparing MCF-7 cells to normal breast, an increase
in L1-ASP containing transcripts is evident when using both controls,
Fig. 5. Increase in expression of L1-ASP containing transcripts is associatedwith DNA hypomethylation. (A) Southern blot of normal and breast cancer genomic DNAs probedwith the
5′UTR of LINE-1. M denotes MspI digest (odd numbered lanes) and H denotes HpaII (even numbered lanes), its methylation-sensitive isoschizomer. Lane 2 shows that LINE-1
elements are heavily methylated in normal breast; however, the digestion of HCC-1954 (lane 4) andMCF-7 (lane 6) genomic DNAwith HpaII reveals there is less LINE-1methylation
in the cancer cell lines. (B) Southern blot ofMspI (M) andHpaII (H) digested genomic DNAs from 5-azacytidine-treated and untreatedMCF-10A cells probedwith the 5′UTR of LINE-1.
Arrows indicate regions of increased cutting suggesting loss of DNAmethylation. Panels A and B were re-probed with a mitochondrial DNA probe to ensure complete digestion (data
not shown). (C) Ethidium bromide stained agarose gel of the semi-quantitative RT–PCRs for L1-ASP, APRT, and 18S transcription in normal breast, MCF-7, MCF-10A, and MCF-10A
treatedwith 1 μM5-azacytidine for 72 hours. (D and E) Four replicates of the semi-quantitative RT–PCRs in panel Cwere analysed by two-dimensional densitometry, and the levels of
L1-ASP expression were normalised to APRT or 18S. Note that, using both controls, there is an increase in L1-ASP containing transcripts in MCF-7 cells compared to normal breast (D)
and in 5-aza-treated MCF-10A cells compared to untreated cells (E), with the differences in the values of the increase observed when using the two controls due to changes in the
expression levels of APRT relatively to 18S.
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18S (Fig. 5D). Similarly, there is a 200% and 88% increase in L1-ASP
transcripts in 5-azacytidine-treated MCF-10A cells compared to
untreated cells relatively to APRT and 18S, respectively (Fig. 5E). The
differences in the relative enrichment observed using APRT and 18S as
controls can be ascribed to differences in APRT expression levels
relatively to 18S, an 11% increase inMCF-7 compared to normal breast
and a 38% reduction in MCF-10A cells following 5-azacytidine
treatment (Figs. 5D and E). Taken together, these ﬁndings suggest
an association between global hypomethylation and a rise in
transcripts containing the L1-ASP.
Expression of cancer-speciﬁc LCTs can be induced in non-neoplastic
breast cells by treatment with 5-azacytidine
Strand-speciﬁc RT–PCR was carried out to analyse the expression
of the seven LCTs described above in 5-azacytidine-treated and
untreated MCF-10A cells. Consistent with the initial observation that
LCT8 and 9 are shared by normal and breast cancer lines, they could bedetected in both treated and untreated cells, with an increase in the
levels of LCT9 seen in 5-azacytidine-treated cells (Fig. 6A). Two
cancer-speciﬁc LCTs were activated in the 5-azacytidine-treated cells
(LCT13 and LCT14) whilst two others remained silenced (LCT15 and
17) (Fig. 6A). Loss of methylation at LCT14, as induced by 5-
azacytidine treatment, was characterised in detail by bisulphite
sequencing (Fig. 6B), revealing that in mock-treated MCF-10A cells,
the L1 5′UTR is substantiallymethylated. In comparison, 5-aza-treated
MCF-10A cells have a subtle loss of DNA methylation at the L1-ASP of
LCT14 paralleling the slight reduction observed by Southern blot
analysis. It seems therefore that a decrease in the levels of DNA
methylation can lead to activation of cancer-speciﬁc chimeric
transcripts in non-neoplastic cells, but the extent to which individual
L1s respond to this may vary.
Discussion
In this study, we devised a strategy to isolate chimeric transcripts
containing L1-ASP and unique DNA sequences. Previously reported
Fig. 6. Induction of cancer-speciﬁc LCTs in normal cells by 5-aza treatment. (A) RT–PCR analysis of L1-ASP-driven chimeras from untreated and treated MCF-10A cells shows
increased transcription of LCT13 and LCT14 in 5-azacytidine-treated cells. (B) Bisulphite sequencing of the sense strand of the L1 5′UTR of LCT14 shows subtle changes in DNA
methylation between mock- and 5-azacytidine-treated MCF-10A cells. Each row of circles represents an individual clone. Open circles are unmethylated CpG dinucleotides and ﬁlled
circles are methylated CpG dinucleotides. All clones had N99% conversion of non-CpG cytosines to uracil.
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screening of oligo-d(T) primed cDNA libraries [2] or the use of
bioinformatics and EST databases [8,9]; however, the LCD technique
described here has no such bias allowing the identiﬁcation of novel
LCTs.Wehave isolated chimeric transcripts thatmay be representative
of read-through transcription (LCT8, 9, and 15), as transcription was
detected upstream of the corresponding L1-ASP, and further work is
necessary to determine whether L1-ASP activation occurs at these
elements. LCT13 and 14 initiate at L1-ASP as shown by 5′RACE, and
LCT17 and 18 are likely to as no upstream transcription was detected.
As shown in Table 1, the L1-ASP-driven transcripts originate not
only at young L1 elements but also at older elements, which have
accumulated mutations that prevent them from retrotransposing;
nevertheless, these have maintained functional elements within their
promoters that allow for transcriptional activation under permissive
conditions. This is an important observation as none of the L1-ASP-
driven LCTs (LCT13, 14, 17, and 18) contain the consensus sequence
for active elements [3] and retrotransposition-competent elements
are only a minority of the full-length L1 elements present in the
genome [3,34]. Future studies may reveal if the effects of transcrip-
tional interference caused by activation of L1-chimeric transcripts are
as extensive as the effects of retrotransposition or genomic rearrange-
ments in cancer.
We have found that L1-driven LCTs are mainly speciﬁc to or
increased in cancer cells compared with normal controls. This
observation is pertinent for both breast and colon cancer cell lines
and consistent with previous observations that L1-driven transcripts
can be cancer-speciﬁc [17,18]. Furthermore, matched normal and
tumour breast samples follow this pattern, suggesting that these
differences reﬂect a cancerous phenotype and not variation in the
activity of L1 elements between individuals as has been found with
reference to retrotransposition [37].
Interestingly, the colon cancer-speciﬁc LCTs are not expressed in
the SW480 colon adenocarcinoma cell line but are present in the
invasive colon carcinoma cell line SW620 isolated from the same
individual. Whilst changes in LCT expression may be due to
differences in the tissue of origin of the cell lines; the SW480/
SW620 is an established model of tumour progression [38] andSW620 have retained the characteristics of colon epithelial cells
[39,40]. Therefore, there is an association between activation of some
LCTs and cancer progression, a similar ﬁnding to that of the MET LCT
[18] and it is tempting to speculate that the activation of LCTs plays a
role in the advancement of cancer to metastasis or has the potential to
act as a novel biomarker for disease progression.
In addition to demonstrating a correlation between hypomethyla-
tion of L1 elements and increased expression of chimeric transcripts,
we have shown that the breast cancer-speciﬁc LCT13 and 14 are
activated by 5-azacytidine treatment of non-malignant MCF-10A
breast epithelial cells. LCT17 and 18 were not activated by
hypomethylation implying that there are other mechanisms at play
in regard to LCT activation or that the decrease in methylation
obtained in MCF-10A was not sufﬁcient for their expression. Never-
theless, these ﬁndings suggest that an increase of chimeric transcripts
can be inﬂuenced by the levels of DNA methylation. As methylation
levels at L1 elements can predict cancer status and outcome [23],
further work is necessary to establish if chimeric transcripts play a
direct role in cancer pathogenesis.
It could be suggested that, as the intronic LCT18 is in a sense
orientation with respect to the KIAA0146 gene in which it resides,
there is potential for the L1-ASP to act as an alternative promoter
producing a truncated version of this gene as has been previously
observed at other genes [8,9]. Moreover, LCTs such as LCT13, 14, and
17 are found in intergenic regions and are likely to represent non-
coding transcripts. Evidence from other systems demonstrates that
sense and antisense intergenic transcription can promote gene
activation [11–13], or silencing [14–16], indicating that the ability of
L1 to drive antisense transcripts may represent an additional way in
which L1 contributes to alterations in gene expression patterns
associated with disease phenotypes. However, further work is
necessary to reveal if activation of L1-chimeric transcripts interferes
with the transcriptional activity of the genes surrounding them.
Our ﬁndings indicate that in addition to the proposed role in
genomic instability and chromosomal rearrangements, activation of
L1 promoters at their original integration site can drive transcription
through neighbouring regions of the genome contributing to changes
in the cancer transcriptome. Future functional analysis of these
404 H.A. Cruickshanks, C. Tufarelli / Genomics 94 (2009) 397–406transcripts is required to establish if they play a causative role in
cancer progression. Furthermore, given the observation that L1
promoters are active early in development [41], L1-driven chimeric
transcripts may play a role in development and differentiation by
shaping the transcriptional status of adjacent chromatin. The LCD
technique described here, combined with high-throughput sequen-
cing technologies, could provide a valuable tool for a systematic and
exhaustive analysis of LCTs in normal development and differentia-
tion, as well as in different cancer types.
Materials and methods
All the primers used in this study and their sequences are listed in
Table 2.
Normal and tumour tissue samples
All samples used in this study were purchased from AMS
Biotechnology or Ambion.
Cell culture
MCF-7 and HCC-1954 (ATCC) cell lines were grown in RPMI 1640
medium (Gibco) with 10% foetal bovine serum (FBS). MCF-10A cellsTable 2
List of oligonucleotides used for LCD and RT–PCR.
Name Sequence (5′ → 3′)
Oligonucleotides used for LCD procedure
(1) LINE-1 speciﬁc primers
RB5PA2 tggaaatgcagaaatcaccg
20a aaatcaccgtcttctgcg
(2) Suppression adapter oligonucleotides (adapted from [30])
42a ggtaatccgacacactgaagggctgggcg
42b ctagagccgccctccgcacc
42c ggtaatccgacacactgaaggg
42d acactgaagggctgggc
Unique oligonucleotides for LCD validation by strand-speciﬁc RT–PCR
(used with LINE-1 speciﬁc primer 20a or 18f)
49b aatatgactttctcttctaaatgg
49c ctctggttattttgaggtatgc
50b ctctgaagtaactccacattgc
50c gtctgacatctttagtaccagc
51b tgagcagtctggtttatggg
51c caatccacgagagaaatgagc
52b gcatgttctcaatggattcc
52c ctgaagtttagtcaagttgagg
53b gcttcattttaatttctgtcatc
53c ttctgtgacttgtaaactctgac
54b tccaaggtcaaacaagttgc
54c ccacactgattggcaagaag
55b agatgaccacagatcagtgc
55c gttgtcactagatgaccacag
Oligonucleotides for strand-speciﬁc and semi-quantitative RT–PCR of LINE-1 ASP and 5′R
18a tacgcccacggaatctcgc
18c aaagaaaggggtgacggtcg
18d ttgtttacctaagcaagcctggg
18e ctttgttccgttgctggtgagg
18f agctcttttagggcaggc
CT51 ccagcaaaggaatgtgttc
CT49 tggagattcagaaagacgccc
CT50 gccctgtggtcactcatactgc
107 ccacgagagaaatgagcagtc
109 ggtcagaggcacacaagaaagttg
18S-RT tctaagggcatcacagacc
4493F agccgcctggataccgcag
5100R agaagttgggggacgccgac
Oligonucleotides for Bisulphite bisulphite sequencing at L1 5′UTR of LCT14
72b ccttacaatttaatctcaaactac
73a tattttagaaattgggagagg
73c ctcaaactactatactaacaatcaac
73b taaaataagtagggagaaaaagag
All the primers were designed for this study with the exception of RB5PA2 as previously dwere grown in mammary epithelial growth medium (Lonza) with
100 ng/ml cholera toxin (Sigma). SW480 and SW620 cells were
maintained in Leibovitz L-15 medium with 1% non-essential amino
acids and 10% FBS. HCT-116 cells were grown in McCoy's 5A medium
with 10% FBS. All cultures were supplemented with 100 μg/ml
penicillin–streptomycin (Invitrogen) and incubated at 37 °C with 5%
CO2.
LINE-1 chimera display (LCD)
First-strand cDNA was synthesised using 5 μg total RNA with
250 ng random primers (Promega) and Superscript II according to the
manufacturer's protocol (Invitrogen). Second-strand synthesis was
then performed with 1× second-strand buffer (Invitrogen), 0.2 mM
dNTPs, 10 U E. coli DNA ligase (NEB), 40 U E. coli DNA polymerase I
(NEB), and 40 U RNase H (NEB) and incubated at 16 °C for 2 hours and
double-strand cDNA was puriﬁed by phenol/chloroform extraction
followed by ethanol precipitation.
Approximately 1 μg of cDNA was digested with 60 U XbaI
overnight. DNA was puriﬁed by phenol/chloroform extraction and
ethanol precipitation. Linker 42ab was ligated to cDNA by T4 ligase
(NEB) at a 20:1 ratio at 16 °C overnight. Excess linkers were removed
by Qiagen PCR Cleanup Kit and puriﬁed by phenol/extraction and
ethanol precipitation. Linker 42ab was prepared by annealingDetails
tggtgcggagggcggct
PCR primer for LCT8
RT primer for LCT8
PCR primer for LCT9
RT primer for LCT9
PCR primer for LCT13
RT primer for LCT13
PCR primer for LCT14
RT primer for LCT14
PCR primer for LCT17
RT primer for LCT17
PCR primer for LCT15
RT primer for LCT15
PCR primer for LCT18
RT primer for LCT18
ACE
Forward primer for L1-ASP
RT primer for L1-ASP
Reverse primer for L1-ASP
Primer for L1 ORF-1 used with LCD validation primers
Primer for L1 ORF-1 used with LCD validation primers
RT primer for APRT
APRT forward primer
APRT reverse primer
LCT13 5′RACE primer
LCT14 5′RACE primer
RT primer for 18S
18S forward primer
18S reverse primer
Forward bisulphite primer
Reverse bisulphite primer
Nested forward bisulphite primer
Nested reverse bisulphite primer
escribed [43].
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10 min; the mix was cooled to 25 °C by reducing the temperature by
1 °C every minute.
PCR ampliﬁcation was carried out with 10 ng of adapter ligated
cDNA with a primer speciﬁc to the outermost region of the adapter
and a primer speciﬁc for L1-ASP, 42c, and RBPA2 (provided by R.
Badge, University of Leicester), respectively. PCR conditions were as
follows: initial denaturation at 95 °C for 3 min, followed by 30 cycles
of denaturation (1 min at 95 °C), annealing (1 min at 59 °C), and
extension (3 min at 72 °C). Nested PCR was performed using 42d,
speciﬁc for the innermost part of the adapter, and 20a speciﬁc to LINE-1
ASP as above except annealing at 51 °C. Products from nested PCR were
directly cloned into pCR2.1 TA cloning vector according to the
manufacturer's protocol (Invitrogen) and those positive for inserts
were sequenced.
Strand-speciﬁc RT–PCR and 5′RACE
Total RNA was extracted from cells using TRI reagent (Sigma) as
manufacturer's instructions. Prior to reverse transcription total RNA
samples were DNaseI-treated as recommended by manufacturer
(Invitrogen). Reverse transcription reactions were carried out using
Superscript II (Invitrogen) as per the manufacturer's protocol and
using 1 μg of DNaseI-treated total RNA as template. One microliter of
ﬁrst-strand cDNAwas used as a template for PCR. PCR conditions were
as follows: 1× Thermo Pol Taq buffer (NEB), 0.2 mM dNTPs
(Amersham), 0.25 μM forward primer, 0.25 μM reverse primer, and
1.25 U Taq polymerase (NEB). PCRs were incubated at 95 °C for 5 min
followed by 30 cycles at 95 °C for 1 min, appropriate annealing
temperature (primer pair dependent) for 1 min and 72 °C for 1 min
with a ﬁnal incubation at 72 °C for 10 min. Gel images were acquired
using a LAS-1000 gel documentation system (Fuji). Semi-quantitative
PCRs were performed by increasing cycle numbers under conditions
optimised for each primer pair (18, 22, and 26 cycles for 18S; 26, 30,
and 34 cycles for L1-ASP and APRT). For semi-quantitative analysis,
two-dimensional densitometry evaluation was performed on four
replicates of each experiment by region determination using the AIDA
(Advanced Image Data Analyser) software (Raytest). The levels of
each amplicon were calculated as the ratio of the mean of the
amplicon values to the mean of the values of the chosen control, and
standard error of the means was used to show the variations. The
levels in MCF-7- and 5-aza-treated MCF-10A cells were expressed as a
percentage of normal breast and untreated MCF-10A cells,
respectively.
For the 5′RACE reactions, the ﬁrst-strand cDNAs were synthesized
in 50 μl reverse transcription (RT) reactions using 5 μg of total RNA
from MCF-7 or SW620 cells, 10 pmol of primers 51c (LCT13), 52c
(LCT14), and CT51 (APRT control), and Expand Reverse Transcriptase
(Roche) in accordance with the manufacturer's directions. The cDNAs
were tailed with poly(dC) using Terminal Transferase (NEB) accord-
ing to the manufacturer's instructions. Three microliters of the tailed
cDNA was then ampliﬁed for 30 cycles using primer 107 in LCT13
unique sequence or 109 in LCT14 unique sequence and the 5′RACE
Anchor primer (Gibco BRL). A second round of PCR was performed on
1 μl of the ﬁrst-round PCR products using primers 51b (LCT13) or 52b
(LCT14) and the Abridged Universal Ampliﬁcation Primer (AUAP,
Gibco BRL). PCRs were performed using the Taq DNA Polymerase
(NEB). 5′RACE products were cloned using the TA cloning kit
(Invitrogen) according to the manufacturer's instructions. Positive
clones were sequenced with M13F and M13R universal primers
(Euroﬁns MWG Operon).
Treatment of cells with 5-azacytidine
MCF-10A cells were seeded at 1×106 with media conditions as
described and grown for 24 hours. 5-Azacytidine (Sigma) prepared indimethyl sulphoxide (DMSO, Sigma) was added to the medium at a
ﬁnal concentration of 1 μM. The media was changed and fresh 5-
azacytidine was added every 24 hours for 72 hours. A ﬂask with an
equivalent amount of DMSO only was included as a mock-treated
control.
Methyl-sensitive Southern blotting
Five micrograms of genomic DNAwas digested with eitherMspI or
its methyl-sensitive isoschizomer HpaII (NEB). Fragments were
separated by agarose gel electrophoresis and DNA was transferred
onto a nylon membrane (BioRad) by upward capillary action in 0.4 M
NaOH. DNA was immobilised on the membrane by baking at 80 °C.
Blots were hybridised with a 32P-radiolabelled probe speciﬁc to the 5′
UTR of human-speciﬁc L1 (a gift from R. Badge, University of
Leicester) in a hybridisation solution (3× SSC, 10 mM EDTA, 0.2%
PVP, 0.2% Ficoll, 0.2% BSA, 0.1% SDS, 0.04 mg/ml salmon sperm DNA
and 0.02 mg/ml heparin, 9% dextran sulphate). The following day,
blots were washed in 2× SSC/0.1% SDS twice for 5 min at room
temperature and twice in 0.1× SSC/0.1× SDS for 15 min at 65 °C.
Membranes were exposed to autoradiograph ﬁlm (Kodak) for
imaging.
Bisulphite sequencing
Onemicrogram of genomic DNAwas digested with an appropriate
restriction enzyme and bisulphite-treated as previously described
[42]. Following treatment, nested PCR was performed using condi-
tions as above. Products were then directly cloned into pCR2.1 TA
cloning vector as per the manufacturer's protocol (Invitrogen) and
those positive for inserts were sequenced.
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